Headlands Technologies’s AstraZeneca AZN Stock Holding History

Headlands Technologies’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-22,153	Closed	-$3.46M	–	1182
2024 Q2	$3.46M	Buy	22,153 +9,098	+70%	+$1.37M	0.37%	59
2024 Q1	$1.77M	Sell	13,055 -2,446	-16%	-$324K	0.42%	56
2023 Q4	$2.09M	Buy	15,501 +14,047	+966%	+$1.83M	0.62%	27
2023 Q3	$197K	Sell	1,454 -5,831	-80%	-$796K	0.1%	204
2023 Q2	$1.04M	Buy	+7,285	New	+$1.07M	0.33%	78
2023 Q1	–	Sell	-3,628	Closed	-$492K	–	508
2022 Q4	$492K	Buy	+3,628	New	+$455K	0.39%	75

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Headlands Technologies's AZN Position: Q3 2024 in Review

Headlands Technologies sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 22,153 shares — an estimated $3.46M sold.

Headlands Technologies first reported a position in AZN in Q4 2022 and held it in 6 quarters. The position peaked at $3.46M in Q2 2024. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

Headlands Technologies reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
Headlands Technologies sold 22,153 AstraZeneca shares in Q3 2024, an estimated $3.46M.
Headlands Technologies first reported a position in AstraZeneca in Q4 2022 and held it in 6 quarters.
Headlands Technologies's AstraZeneca position peaked at $3.46M in Q2 2024.
1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Headlands Technologies's 13F filing for Q3 2024, filed 12 Nov 2024.